INTRODUCTION
Allergy Asthma Immunol Res. 2015 January;7(1):37-43. http://dx.doi.org/10.4168/aair.2015.7.1.37 previously reported as a major allergen of buckwheat, shows IgE reactivity on most patients regardless of their symptoms. 9, 10 Fag e 2 (16 kDa), a member of 2S albumin, is highly resistant to peptic hydrolysis 11, 12 and is the most allergenic protein. 13 Fag e 3 (19 kDa), a vicilin, has no homology with other buckwheat allergens and distinguishes symptomatic individuals from asymptomatic patients more exclusively. The 10 kDa protein (Fag e 10 kDa) is classified as 2S albumin and was reactive to buckwheat in 57% of patients in a previous study. 14 There have been only a few reports in the literature regarding the difference in allergens according to the clinical severity of buckwheat allergy, although specific allergens could be associated with clinical manifestations of different severity. 15 Predicting the clinical severity would be valuable in the management of patients with buckwheat allergy. Therefore, we investigated the relationship between the allergen components and moderateto-severe allergic reactions in patients with buckwheat allergy.
MATERIALS AND METHODS

Subjects
We enrolled patients with a history of buckwheat ingestion and buckwheat sensitization at the Allergy Clinic of Samsung Medical Center. Buckwheat sensitization was defined as the buckwheat sIgE level≥0.35 kU/L by using the ImmunoCAP system (Thermo Fisher Scientific, Waltham, MA, USA). History of allergic symptoms after eating buckwheat was evaluated and clinical severity of symptoms were assessed on a 0-5 scale with a reported grading system of peanut allergy 16 : 0 indicating no symptoms; 1 indicating abdominal pain that resolved without medical treatment, rhinoconjunctivitis, urticaria fewer than 10 papules, or rash (eczema onset); 2 indicating 1 organ involved, abdominal pain requiring treatment, generalized urticaria, non-laryngeal angioedema, or mild asthma (cough or fall of peak expiratory flow<20%); 3 indicating 2 organs involved; 4 indicating 3 organs involved, asthma requiring treatment, laryngeal edema or hypotension; and 5 indicating cardiac and respiratory symptoms requiring hospitalization in intensive care. Patients were divided into 2 groups based on the clinical severity: asymptomatic-to-mild (grades 0-1) and moderate-to-severe (grades 2-4) group. After written informed consent was received, blood samples were obtained and the serum samples were frozen at -80°C until use. This study was approved by the Samsung Medical Center institutional review board (IRB No. 2012-06-047-001).
Buckwheat protein extraction
Buckwheat protein was extracted as described by Tanaka et al. 11 with minor modifications using Buckwheat powder (Fagopyrum esculentum, National Agricultural Cooperative Federation, Bong-pyung, Korea). Five grams of finely ground buckwheat was extracted overnight by shaking at 4°C in 50 mL 0.086 M NaCl (Showa, Gyoda, Japan) solution containing 0.033 M NaHCO3 (Duksan, Ansan, Korea). After centrifugation at 12,000 g for 30 minutes, the supernatant was filtered with a 3,000 Da ultrafilter (Millipore, Cork, Ireland) to exclude proteins exceeding 3,000 Da, and freeze-dried at -80°C . It was stored at -70°C until use. The protein concentrations were then determined by a Bradford Assay (Bio-Rad, Hercules, CA, USA) using a microplate reader (Bio-Rad).
Electrophoresis and immunoblotting
The protein extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method described by Laemmli. 17 The samples were then reduced by heating with 4x SDS-PAGE gel loading buffer (LDS Sample Buffer, Novex, Carlsbad, CA, USA), mixed 1:10 with reducing agent (Novex, Carlsbad, CA, USA), and loaded into each well of a 4%-12% Bis-Tris Aminomethane Gel (NuPAGE; Invitrogen, Carlsbad, CA, USA). Precision plus protein standards (BioRad) were used as molecular weight markers to estimate the protein size. For immunoblotting, proteins from buckwheat were transferred from the gel onto a polyvinylidene difluoride membrane using an iBlot Dry Blotting System (Invitrogen). The membrane was blocked with 2% nonfat dried milk (NFDM) for 1 hour at room temperature, after which it was incubated with the serum samples diluted 1:10 in 2% NFDM for overnight at 4°C. The membrane was then washed 3 times with phosphatebuffered saline containing 0.03% Tween-20 (PBST) for 10 minutes each and incubated with biotin-labeled goat IgG anti-human IgE (KPL, Gaithersburg, MD, USA) diluted 1:4,000 in 2% NFDM for 1 hour at room temperature. Next, the membrane was washed three times with PBST as described, after which it was incubated with NeutrAvidin horseradish peroxidase (Pierce Chemical, Rockford, IL, USA) for 30 minutes at room temperature. After three PBST washes, the membrane was reacted with ECL reagent (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) for 2 minutes. The membrane was then exposed to high-performance chemiluminescence film (GE Healthcare Limited, Buckinghamshire, UK), after which the film was developed.
Comparison of IgE reactivity to each component between groups
The band intensity of immunoblots of buckwheat proteins were measured using a reflective densitometer (Bio-Rad). Detection of an individual protein band was defined as optical density (OD/mm 2 ) more than 2 standard deviations (SD) from the mean in backgrounds.
Statistical analysis
For the statistical analysis, values>100 kUA/L were assigned a value of 101 kUA/L. Total IgE, buckwheat sIgE, relative optical density (OD) of immunoblots of each buckwheat protein (16, 24, 30, (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) 75 , and 100 kDa) were analyzed between the grade Allergy Asthma Immunol Res. 2015 January;7(1):37-43. http://dx.doi.org/10.4168/aair.2015.7.1.37 0-1 and grade 2-4 groups using Mann-Whitney U-tests. The proportions of positive band to the allergens were analyzed between the grade 0-1 and grade 2-4 groups using Fisher's exact test. A P value<0.05 was considered significant. The analysis was performed using SPSS for Windows (version 20.0; Chicago, IL, USA).
RESULTS
Fifteen patients (12 boys and 3 girls) were included in this study (median age, 5 years). Seven subjects presented with grade 0-1 allergic symptoms after ingestion of buckwheat, and eight subjects had grade 2-4 allergic reactions requiring treatment ( Table 1 The sera in the grade 0-1 group presented with weak IgE binding intensity with buckwheat proteins, except that of patients 1 and 2. On the other hand, the sera in the grade 2-4 group showed strong IgE binding activity with buckwheat proteins components. Notably, 40-50 kDa and 16 kDa among the protein components showed strong IgE binding intensity in the grade 2-4 group, except subject 8. In addition, IgE binding intensities against 16 kDa were very strong for 5 patients (No. 9, 11, 12, 13, and 15) in the grade 2-4 group than in the grade 0-1 group. The level of buckwheat sIgE of grade 2-4 group was higher than that of grade 0-1 group (41.3 kU/L vs 5.5 kU/L, P=0.037) (Fig. 2) . The median ODs of IgE antibody binding to 40-50 kDa protein were also higher in the grade 2-4 group, compared with those in the grade 0-1 group (130% OD vs 60.8% OD, P=0.037). However, there were no differences in total IgE levels and binding activity to 16, 24, 30, 75 , and 100 kDa proteins between the 2 groups (P=0.165, 0.203, 0.728, 0.355, 0.165, and 0.908).
DISCUSSION
Buckwheat is a major food allergen that can cause severe allergic reactions, such as anaphylaxis, in Korean children. 18, 19 To confirm buckwheat allergy using double-blind placebo-controlled food challenge (DBPCFC) is time-consuming and can be life-threatening, although it is the diagnostic gold standard of food allergy. 20 The measurements of food sIgE antibody levels and sIgE to individual components could be a useful method for diagnosing symptomatic allergy and for predicting the clinical severity in a large number of children that may eliminate the need to perform DBPCFC. 21 However, controversy exists concerning the usefulness of food sIgE levels for the prediction of clinical allergy, 22, 23 and the reactivity to different buckwheat allergens has not been evaluated for its contribution to clinical patterns of patients with buckwheat allergy. The present study implicates the 40-50 kDa cluster and 16 kDa buckwheat proteins as important allergens to predict moderate-to-severe (grade 2-4) symptoms in Korean children. In addition, the level of buckwheat sIgE was significantly higher in the moderate-tosevere (grade 2-4) group, suggesting that buckwheat sIgE could be applicable for predicting more severe reaction in a clinical setting.
In the present study, 16, 24, 30, 40-50, 75, and 100 kDa were IgEreactive proteins and 16 kDa, 24 kDa, and 40-50 kDa (40, 45, 48 kDa) were major allergens. IgE bindings to 40-, 45-, and 48-kDa were shown in a similar pattern, so 40-, 45-, and 48-kDa were analyzed in cluster (40-50 kDa). The immunologic profiles of buckwheat allergens have been studied by several investigators. Nagata et al. 24 described that the 24 kDa molecule was the most prominent allergen recognized with IgE. Yoshimasu et al. 12 reported that IgE binding was detected to proteins with molecular masses of approximately 14 and 18 kDa. Park et al. 25 showed that the allergens of 24, 19, 16, and 9 kDa were strong candidates to be major allergens, and the 19-kDa allergen was relatively specific for buckwheat-allergic patients. Heffer et al. 15 identified several IgEbinding proteins and grouped proteins into three patterns: a 16-kDa band in patients with predominantly gastrointestinal symptoms with grass and wheat flour co-sensitization, a 25-kDa band in patients with predominantly cutaneous symptoms and a low frequency of co-sensitization, and a 40-kDa band in patients with anaphylaxis and a low frequency of co-sensitization. Although a variety of allergens were reported, only 3 allergens, Fag e 1 (24 kDa), Fag e 2 (16 kDa), and Fag e 3 (19 kDa) have been considered as major allergens. We found that 40-, 45-, and 48-kDa proteins reacted with specific IgE from patients with buckwheat allergy, especially those who had moderate-to-severe clinical symptoms. The role of these proteins in buckwheat allergy may have been underestimated, even though 40 kDa was reported to be associated with anaphylaxis 15 and 45-, and 48-kDa were mentioned in previous papers. 24, 25 Fag e 3 (19 kDa) was the most specific buckwheat allergen in a Korean study, 25 while it did not react with specific IgE in other studies. 15, 24 In this study, we could not find the immune reaction with serum from our patients with buckwheat allergy. It might be due to small number of study population and differences in various factors such as ethnicity, age, feeding habits or cooking conditions. [25] [26] [27] Some specific components of crude allergen are reportedly useful to discriminate symptomatic allergic patients from asymptomatic sensitized subject in some foods such as peanut, kiwifruit, carrot and soybean. [28] [29] [30] [31] [32] In the present study, we quantitatively analyzed immunoblotting profile using OD to measure the binding activity of all specific buckwheat components and investigated the relation of the specific allergens with severe allergic reaction. Specific protein components, 40 kDa, 45 kDa, 48 kDa, and 16 kDa, were more reactive to IgE from the subjects with grade 2-4 symptoms than those with grade 0-1 symptoms in immunoblotting profiles. These results imply that specific allergen components may be associated with severe clinical symptom. Fag e 2, a 2S albumin, is refractory to peptic hydrolysis [11] [12] [13] and measurement of the sIgE to 16 kDa protein is more discriminating than sIgE to whole buckwheat extracts for the diagnosis of clinical reactivity to buckwheat. 7 Tanaka et al. 15 reported that the association of 16 kDa protein with gastrointestinal symptoms, 25 kDa protein with cutaneous symptoms and 40 kDa protein with anaphylaxis, suggesting that specific allergens could be more frequently associated with clinical manifestations of different severity. Our study showed consistent results with these previous studies 11, 15 and also suggest that further studies on the significance of buckwheat allergens are needed.
This study has some limitations. One is its small sample size and another is that we could not use the DBPCFC test to confirm buckwheat allergy. Considering severe symptoms of buckwheat allergy, it was hard to repeat symptom provocation. Despite the limitations, this study has provided useful information regarding buckwheat allergy.
In conclusion, 40-, 45-, 48-, and 16-kDa proteins in buckwheat may act as important allergens in severe clinical symptoms in patients with buckwheat allergy. Quantitative and qualitative measurements of specific components in buckwheat proteins may be helpful for predicting significant clinical symptoms.
